Targeting the Peripheral T-Cell Lymphoma (Ptcl) Epigenome With Oral 5-Azacytidine and Romidepsin: Results and Clinical-Molecular Correlations From a Phase 2 Study

Hematological Oncology - United Kingdom
doi 10.1002/hon.135_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Oral Azacytidine (Aza) and Romidepsin (R) Reveals Promising Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase 1 Study of Pralatrexate Plus Romidepsin Reveals Marked Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Laboratory Correlates for a Phase II Trial of Romidepsin in Cutaneous and Peripheral T-Cell Lymphoma

British Journal of Haematology
Hematology
2010English

A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Peripheral T-Cell Lymphoma (PTCL): Final Results From the T- Cell Consortium Trial

British Journal of Haematology
Hematology
2015English

Phase I Study of Romidepsin and Liposomal Doxorubicin in Relapsed or Refractory T-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pcn334 - Outcomes of Peripheral T-Cell Lymphoma (Ptcl) Patients Treated in the Real World

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Correction To: Multicenter Phase 1/2 Study of Forodesine in Patients With Relapsed Peripheral T Cell Lymphoma

Annals of Hematology
MedicineHematology
2018English

PRELIMINARY RESULTS OF ASTX660, a NOVEL NON-PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-Cell LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy